...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease
【24h】

Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease

机译：超声心动图得出的三尖瓣反流喷射速度在镰状细胞病中的纵向研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although echocardiography-derived tricuspid regurgitant jet velocity (TRV) is associated with increased mortality in sickle cell disease (SCD), its rate of increase and predictive markers of its progression are unknown. We evaluated 55 subjects (median age: 38 years, range: 20-65 years) with at least two measurable TRVs, followed for a median of 4·5 years (range: 1·0-10·5 years) in a single-centre, prospective study. Thirty-one subjects (56%) showed an increase in TRV, while 24 subjects (44%) showed no change or a decrease in TRV. A linear mixed effects model indicated an overall rate of increase in the TRV of 0·02 m/s per year (P = 0·023). The model showed that treatment with hydroxycarbamide was associated with an initial TRV that was 0·20 m/s lower than no such treatment (P = 0·033), while treatment with angiotensin converting enzyme inhibitors and angiotensin receptor blockers was associated with an increase in the TRV (P = 0·006). In summary, although some patients have clinically meaningful increases, the overall rate of TRV increase is slow. Treatment with hydroxycarbamide may decrease the progression of TRV. Additional studies are required to determine the optimal frequency of screening echocardiography and the effect of therapeutic interventions on the progression of TRV in SCD.
机译：尽管超声心动图得出的三尖瓣反流射流速度（TRV）与镰状细胞病（SCD）的死亡率增加相关，但其增加速率和其进展的预测标志物尚不清楚。我们评估了55名受试者（中位年龄：38岁，范围：20-65岁），至少有两个可测量的TRV，然后在单项研究中中位数为4·5年（范围：1·0-10·5年）。中心，前瞻性研究。 31名受试者（56％）的TRV升高，而24名受试者（44％）的TRV不变或降低。线性混合效应模型表明，TRV的总体增长率为每年0·02 m / s（P = 0·023）。该模型显示，使用羟基脲进行治疗的初始TRV比不进行治疗的初始TRV低0·20 m / s（P = 0·033），而使用血管紧张素转化酶抑制剂和血管紧张素受体阻滞剂治疗的初始TRV升高在TRV中（P = 0·006）。总而言之，尽管某些患者在临床上有有意义的增加，但TRV的总体增加速度缓慢。用羟基脲治疗可能会降低TRV的进程。需要进行其他研究以确定超声心动图筛查的最佳频率以及治疗干预对SCD中TRV进展的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号